{ "items": [ "\n\n
\n \n\n \n \n \n \n Nuffield Division of Clinical Laboratory Sciences\n \n \n\n \n\n\n
\n \n \n \nWe are developing gene therapy for lung conditions, including the genetic disease Cystic Fibrosis (CF) and neonatal lung conditions such as surfactant protein B (SPB) deficiency. We are also evaluating whether the lung can be used as a \u2018protein factory\u2019 to make therapeutic proteins such as antibodies.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n \n \n Oxford Centre for Clinical Magnetic Resonance Research\n \n \n\n \n\n\n
\n \n \n \nWe have expertise in the study of heart disease using cardiovascular magnetic resonance (CMR), particularly quantitative techniques such as myocardial T1-mapping.
\n \n\n \n \n\n \n\n \n \n \n \n Oxford Centre for Diabetes, Endocrinology and Metabolism\n \n \n\n \n\n\n
\n \n \n \nThe Diabetes Trials Unit (DTU) is a clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nThe CRM group\u2019s principal research interests are the treatment of abnormal heart rhythms and the resynchronisation of abnormal electrical conduction in heart failure patients. There is a particular focus on the use of novel and emerging technologies.
\n \n\n \n \n\n \n\n \n \n \n \n Investigative Medicine Division\n \n \n\n \n\n\n
\n \n \n \nThe Laboratory of Cerebral Ischemia is a pre-clinical research group aiming to discover both the mechanisms which underlie cell death in stroke and to develop novel strategies to reduce this.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe work to understand how early changes in cells of the cardiovascular system, such as endothelial cells and leukocytes, are related to cardiovascular disease, with a particular focus on redox biology.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nUsing human genetics and functional genomics to understand inherited heart disease
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe make about 1600 patient contacts a year with those who have, or are at risk of having, an Inherited Cardiac Condition (eg cardiomyopathies and inherited arrhythmias) across all age ranges. We provide cardiology screening (ECG, Echocardiography) and clinical genetics during an initial single clinic visit, and provide telephone and e-mail support throughout the working week. We have made internationally recognised contributions in this area, in particular the use of cardiac MRI in diagnosis, and understanding of the underlying genetic basis of Inherited Cardiac Conditions.
\n \n\n \n \n\n \n\n \n \n \n \n Cardiovascular Clinical Research Facility\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur aim is to develop better ways to identify early disease and improve cardiovascular health for young people. This is achieved by undertaking work in three areas: (1) Identification of novel markers of early disease to better understand how disease becomes established (2) Performing cardiovascular prevention trials in young adults to understand how to modify early disease and improve health (3) Application of artificial intelligence to imaging and research datasets to identify next generation imaging and management approaches.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nUse of minimally invasive techniques to improve heart function.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur goals are to develop therapeutics targeting the chemokine network in inflammatory diseases affecting the heart, blood vessels and other organ systems.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe study how the heart meets its high and variable energy demands in order to identify novel strategies that may be beneficial in disease.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nNitric oxide regulation of cardiac function, metabolism and inflammation in diabetes.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe research genetic diseases of the heart (cardiomyopathies) that can lead to sudden cardiac death. An example of an individual with cardiomyopathy is the professional football player Fabrice Muamba, who collapsed on the pitch and had to be resuscitated. He was fortunate to survive his cardiac arrest and his case was featured in the media.
\n \n\n \n \n\n \n\n \n \n \n \n Acute Multidisciplinary Imaging and Interventional Centre\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nThis translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nDefining the function of new causal atherosclerosis genes from CAD GWAS loci using in vitro and in vivo models.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur programme of work aims to understand nitric oxide (NO) and redox signalling in healthy and diseased myocardium, with a particular focus on atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Building on the resources and original discoveries that we have made recently, we plan to test novel interventions that aim to correct the myocardial substrate that promotes the new onset of AF, or HFpEF, or prevent the adverse atrial remodelling that is induced by AF.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n \n \n Oxford Centre for Clinical Magnetic Resonance Research\n \n \n\n \n\n\n
\n \n \n \nWe investigate diseases of the heart valves \u2013 how widespread the problem is, what the causes are, who is at risk from future problems and what treatments can improve outcomes for patients.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n \n \n Oxford Centre for Clinical Magnetic Resonance Research\n \n \n\n \n\n\n
\n \n \n \nWe use multi-parametric cardiac magnetic resonance imaging and multinuclear magnetic resonance spectroscopy to non-invasively investigate the relationship between cardiac metabolism and cardiac function.
\n \n\n \n \n